Market closedNon-fractional
iCAD/ICAD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About iCAD
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.
Ticker
ICAD
Sector
Healthcare
Trading on
NASDAQ
Industry
Health Care Technology
Headquarters
Nashua, United States
Employees
68
Website
www.icadmed.com
iCAD Metrics
BasicAdvanced
$35M
Market cap
-
P/E ratio
-$0.09
EPS
1.50
Beta
-
Dividend rate
Price and volume
Market cap
$35M
Beta
1.5
Financial strength
Current ratio
4.715
Quick ratio
4.35
Long term debt to equity
0.943
Total debt to equity
1.608
Interest coverage (TTM)
-368.13%
Management effectiveness
Return on assets (TTM)
-8.37%
Return on equity (TTM)
-16.02%
Valuation
Price to revenue (TTM)
1.905
Price to book
1.09
Price to tangible book (TTM)
1.47
Price to free cash flow (TTM)
-5.729
Growth
Revenue change (TTM)
7.98%
Earnings per share change (TTM)
-83.92%
3-year revenue growth (CAGR)
-17.37%
3-year earnings per share growth (CAGR)
-35.13%
What the Analysts think about iCAD
Analyst Ratings
Majority rating from 3 analysts.
iCAD Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$4.9M
4.26%
Net income
-$1.2M
-160.00%
Profit margin
-24.48%
-157.53%
iCAD Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.07
-$0.05
$0.05
-$0.05
-
Expected
-$0.11
-$0.09
-$0.05
-$0.06
-$0.07
Surprise
-36.36%
-44.44%
-193.75%
-21.05%
-
iCAD News
AllArticlesVideos
iCAD to Highlight Promising Research on Potential of its AI Algorithm to More Accurately Identify and Personalize Breast Cancer Risk at SIIM 2024
GlobeNewsWire·1 month ago
iCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference
GlobeNewsWire·2 months ago
iCAD Reports Financial Results for First Quarter Ended March 31, 2024
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for iCAD stock?
iCAD (ICAD) has a market cap of $35M as of July 27, 2024.
What is the P/E ratio for iCAD stock?
The price to earnings (P/E) ratio for iCAD (ICAD) stock is 0 as of July 27, 2024.
Does iCAD stock pay dividends?
No, iCAD (ICAD) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next iCAD dividend payment date?
iCAD (ICAD) stock does not pay dividends to its shareholders.
What is the beta indicator for iCAD?
iCAD (ICAD) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell iCAD stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.